NetworkNewsBreaks – Lexaria Bioscience Corp. (CS

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Files New Patent Application Following Breakthrough Discovery of Enhanced Drug Delivery to Brain Tissue

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) this morning announced that it has filed a new patent application with the United States Patent and Trademark Office ("USPTO" for innovation in treatment options related to central nervous system disease or disorders including viral infection, cancer, neurodegenerative disorders, ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer's, Huntington's, Parkinson's, neuropathic pain and more. The company reached a breakthrough discovery during recent laboratory testing that demonstrated significantly enhanced drug delivery to brain tissue. Evidence from the study showed unexpected effectiveness in crossing the blood-brain barrier ("BBB" which Lexaria is investigating more extensively, leading to the company's patent application titled: "Enhancement of Delivery of Lipophilic Active Agents Across the Blood-Brain Barrier and Methods for Treating Central Nervous System Disorders." Discovery of DehydraTECH™ technology’s apparent effectiveness in crossing the BBB suggests the potential to deliver other therapeutic drugs using DehydraTECH™ in the treatment of intractable diseases. Lexaria's application requests patent protection for the delivery of cannabinoids, terpenes and terpenoids, non-steroidal anti-inflammatory drugs (“NSAIDs”), vitamins, nicotine, phosphodiesterase type 5 (“PDE5”) inhibitors, estrogen, progestin, testosterone, scopolamine and more, employing the company’s already-patented DehydraTECH™ methodology combined with any of a wide assortment of emulsifiers, starches, oils, flavorings and foods.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer